Kristen L. Arienti
Iowa State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kristen L. Arienti.
Bioorganic & Medicinal Chemistry Letters | 1999
Robert I. Higuchi; James P. Edwards; Thomas R. Caferro; Josef D. Ringgenberg; James Kong; Lawrence G. Hamann; Kristen L. Arienti; Keith B. Marschke; Robert L. Davis; Luc J. Farmer; Todd K. Jones
A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.
Journal of Biological Chemistry | 2003
Jun-young Choe; Scott W. Nelson; Kristen L. Arienti; Frank U. Axe; Tassie L. Collins; Todd K. Jones; Rachel D.A. Kimmich; Michael J. Newman; Karl Norvell; William C. Ripka; Suzanne J. Romano; Kevin M. Short; Deborah H. Slee; Herbert J. Fromm; Richard B. Honzatko
A highly constrained pseudo-tetrapeptide (OC252-324) further defines a new allosteric binding site located near the center of fructose-1,6-bisphosphatase. In a crystal structure, pairs of inhibitory molecules bind to opposite faces of the enzyme tetramer. Each ligand molecule is in contact with three of four subunits of the tetramer, hydrogen bonding with the side chain of Asp187 and the backbone carbonyl of residue 71, and electrostatically interacting with the backbone carbonyl of residue 51. The ligated complex adopts a quaternary structure between the canonical R- and T-states of fructose-1,6-bisphosphatase, and yet a dynamic loop essential for catalysis (residues 52-72) is in a conformation identical to that of the T-state enzyme. Inhibition by the pseudo-tetrapeptide is cooperative (Hill coefficient of 2), synergistic with both AMP and fructose 2,6-bisphosphate, noncompetitive with respect to Mg2+, and uncompetitive with respect to fructose 1,6-bisphosphate. The ligand dramatically lowers the concentration at which substrate inhibition dominates the kinetics of fructose-1,6-bisphosphatase. Elevated substrate concentrations employed in kinetic screens may have facilitated the discovery of this uncompetitive inhibitor. Moreover, the inhibitor could mimic an unknown natural effector of fructose-1,6-bisphosphatase, as it interacts strongly with a conserved residue of undetermined functional significance.
Journal of Medicinal Chemistry | 2007
Robert I. Higuchi; Kristen L. Arienti; Francisco J. López; Neelakhanda S. Mani; Dale E. Mais; Thomas R. Caferro; Yun Oliver Long; Todd K. Jones; James P. Edwards; Lin Zhi; William T. Schrader; and Andrés Negro-Vilar; Keith B. Marschke
Archive | 2002
Kristen L. Arienti; Frank U. Axe; J. Guy Breitenbucher; Liming Huang; Alice Lee; Kelly J. Mcclure
Archive | 1999
Adnan M. M. Mjalli; James Christopher Mason; Kristen L. Arienti; Kevin M. Short; Rachel D.A. Kimmich; Todd K. Jones
Archive | 2006
Michael K. Ameriks; Kristen L. Arienti; Frank U. Axe; J. Guy Breitenbucher
Archive | 2008
Michael K. Ameriks; Kristen L. Arienti; James P. Edwards; Cheryl A. Grice; Todd K. Jones; Alice Lee-Dutra; Jing Liu; Neelakandha S. Mani; Danielle K. Neff; Alvah T. Wickboldt; John J. M. Wiener
Archive | 2004
Michael K. Ameriks; Kristen L. Arienti; Frank U. Axe; J. Guy Breitenbucher
Archive | 2004
Kristen L. Arienti; J. Guy Breitenbucher; Daniel J. Buzard; James P. Edwards; Michael D. Hack; Haripada Khatuya; David E. Kindrachuk; Alice Lee; Jennifer D. Venable
Archive | 2002
Kristen L. Arienti; Frank U. Axe; J. Guy Breitenbucher; Liming Huang; Alice Lee; Kelly J. Mcclure